NCT07474961 2026-03-16
BLOOD-dose
Rigshospitalet, Denmark
Phase 4 Not yet recruiting
Clinical Trials
186 trialsNCT06049134 2026-03-09
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
M.D. Anderson Cancer Center
Phase 4 Active not recruiting
NCT06035757 2026-03-03
The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery
Konkuk University Medical Center
Phase 4 Recruiting
NCT06289673 2026-03-03
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
St. Jude Children's Research Hospital
Phase 4 Recruiting
NCT06876649 2026-03-02
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Eli Lilly and Company
Phase 4 Recruiting
NCT06651970 2026-02-23
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
AstraZeneca
Phase 4 Recruiting
NCT07426484 2026-02-23
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
Phase 4 Not yet recruiting
NCT02844309 2026-02-11
BDH-WM02
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Completed
NCT02844322 2026-02-11
BDH-WM01
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Completed
NCT02844361 2026-02-11
BDH-WM03
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Completed
NCT07218341 2026-02-10
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Eli Lilly and Company
Phase 4 Not yet recruiting
NCT05170399 2026-02-05
Vaccine Responses in Patients With B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 4 Recruiting
NCT07167862 2026-01-23
PPPOCUS
University of California, Irvine
Phase 4 Not yet recruiting
NCT07355699 2026-01-21
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
Beijing Tongren Hospital
Phase 4 Recruiting
NCT07320534 2026-01-08
Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase
Gadjah Mada University
Phase 4 Not yet recruiting
NCT04091009 2025-12-31
Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post-Operative Opioid Use Disorder Symptoms
Massachusetts General Hospital
Phase 4 Withdrawn
NCT06752850 2025-12-19
A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis
Swedish Orphan Biovitrum
Phase 4 Active not recruiting
NCT07169331 2025-12-19
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia
BeOne Medicines
Phase 4 Recruiting
NCT07270146 2025-12-08
Effectiveness and Safety of Guilu Erxian Oral Liquid in the Treatment of Oligozoospermia and Asthenospermia With Syndrome of Shen (Kidney) Essence Deficiency
DongE E Jiao Coporation Limited
Phase 4 Completed
NCT07270835 2025-12-08
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
The First Affiliated Hospital of Soochow University
Phase 4 Recruiting
NCT05687032 2025-12-03
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Pfizer
Phase 4 Completed
NCT03229200 2025-10-30
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Pharmacyclics Switzerland GmbH
Phase 4 Active not recruiting
NCT01909934 2025-09-19
Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Takeda
Phase 4 Completed
NCT05442554 2025-09-18
A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma
Takeda
Phase 4 Completed
NCT06285370 2025-09-18
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
Kyowa Kirin Co., Ltd.
Phase 4 Active not recruiting
NCT05160922 2025-09-03
Crizotinib Continuation Clinical Study
Pfizer
Phase 4 Active not recruiting
NCT07016165 2025-08-22
Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
Gadjah Mada University
Phase 4 Recruiting
NCT04460235 2025-07-01
HEMATOVAC
Poitiers University Hospital
Phase 4 Recruiting
NCT04506086 2025-05-18
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 4 Terminated
NCT06956092 2025-05-02
Glofitamab
Zhengzhou University
Phase 4 Not yet recruiting
NCT05071482 2025-05-01
Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Terminated
NCT06918054 2025-04-09
Hepatoprotective for Children and Adolescent With Acute Lymphoblastic Leukemia
Ain Shams University
Phase 4 Recruiting
NCT06918080 2025-04-09
Hepatoprotective Measures for Children at High Risk of NAFLD
Ain Shams University
Phase 4 Active not recruiting
NCT05108805 2025-03-27
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
Vanderbilt-Ingram Cancer Center
Phase 4 Completed
NCT04060654 2025-03-25
SUBLOCADE Rapid Initiation Extension Study
Indivior Inc.
Phase 4 Completed
NCT04726501 2025-02-13
CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma
Children's Cancer Group, China
Phase 4 Recruiting
NCT01804166 2025-02-04
A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
Janssen Scientific Affairs, LLC
Phase 4 Completed
NCT06665737 2025-01-28
G-CSF in NHL
Department of Medical Services Ministry of Public Health of Thailand
Phase 4 Not yet recruiting
NCT06711679 2024-12-02
Exploring the Minimum Effective Concentration and Volume of Ropivacaine for Sacral Plexus Anesthesia
Tongji Hospital
Phase 4 Enrolling by invitation
NCT04930536 2024-11-22
Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
AstraZeneca
Phase 4 Completed
NCT05806580 2024-10-23
Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma
Ruijin Hospital
Phase 4 Recruiting
NCT06609304 2024-10-15
axi-cel
Zhengzhou University
Phase 4 Recruiting
NCT05784844 2024-09-19
Antimicrobial Revision in Persistent Febrile Neutropenia
Wake Forest University Health Sciences
Phase 4 Withdrawn
NCT06134284 2024-06-11
Clinical Study of OR for Second-line Treatment of Refractory MZL
Ningbo No. 1 Hospital
Phase 4 Recruiting
NCT06410833 2024-05-16
BRRPJS
Peking Union Medical College Hospital
Phase 4 Recruiting
NCT05545202 2024-04-03
A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
Pharmacosmos A/S
Phase 4 Not yet recruiting
NCT04846855 2024-02-12
RATAPED
Ramsay Générale de Santé
Phase 4 Completed
NCT01735955 2024-02-08
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Novartis
Phase 4 Completed
NCT01088750 2023-12-13
EuroNetLP1
Martin-Luther-Universität Halle-Wittenberg
Phase 4 Completed
NCT03677596 2023-11-22
A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients
Pfizer
Phase 4 Completed